Evidence map›Paper›PMID 39096293›Full record

ArticleACS nano2024

Paracellular Delivery of Protein Drugs with Smart EnteroPatho Nanoparticles.

Isabela Ramirez-Velez, Aditya A Namjoshi, Unyime M Effiong, Nicholas A Peppas, Brian Belardi

Abstract read
In one paragraph

Article in ACS nano, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Designing the Next Generation of Biomaterials through Nanoengineering.Advanced materials (Deerfield Beach, Fla.) · 2025
    Review
  2. Review
  3. Review
  4. Enteral Route Nanomedicine for Cancer Therapy.International journal of nanomedicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Isabela Ramirez-VelezMcKetta Department of Chemical Engineering, The University of Texas at Austin, Austin, Texas 78712, United States.ORCID 0000-0002-5531-1573
Aditya A NamjoshiMcKetta Department of Chemical Engineering, The University of Texas at Austin, Austin, Texas 78712, United States.
Unyime M EffiongMcKetta Department of Chemical Engineering, The University of Texas at Austin, Austin, Texas 78712, United States.ORCID 0009-0007-7637-4147
Nicholas A PeppasMcKetta Department of Chemical Engineering, The University of Texas at Austin, Austin, Texas 78712, United States.ORCID 0000-0003-0894-5626
Brian BelardiMcKetta Department of Chemical Engineering, The University of Texas at Austin, Austin, Texas 78712, United States.ORCID 0000-0003-3608-0164

Funding

A Molecular Toolkit for Controlling and Probing Cell Junction-Actin InteractionsR35GM142941 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI BELARDI, BRIAN · 2021 to 2025
$1.9M
NIGMS NIH HHS R35 GM142941
6 · The paper itself

Abstract

A general platform for the safe and effective oral delivery of biologics would revolutionize the administration of protein-based drugs, improving access for patients and lowering the financial burden on the health-care industry. Because of their dimensions and physiochemical properties, nanomaterials stand as promising vehicles for navigating the complex and challenging environment in the gastrointestinal (GI) tract. Recent developments have led to materials that protect protein drugs from degradation and enable controlled release in the small intestine, the site of absorption for most proteins. Yet, once present in the small intestine, the protein must transit through the secreted mucus and epithelial cells of the intestinal mucosa into systemic circulation, a process that remains a bottleneck for nanomaterial-based delivery. One attractive pathway through the intestinal mucosa is the paracellular route, which avoids cell trafficking and other degradative processes in the interior of cells. Direct flux between cells is regulated by epithelial tight junctions (TJs) that seal the paracellular space and prevent protein flux. Here, we describe a smart nanoparticle system that directly and transiently disrupts TJs for improved protein delivery, an unrealized goal to-date. We take inspiration from enteropathogenic bacteria that adhere to intestinal epithelia and secrete inhibitors that block TJ interactions in the local environment. To mimic these natural mechanisms, we engineer nanoparticles (EnteroPatho NPs) that attach to the epithelial glycocalyx and release TJ modulators in response to the intestinal pH. We show that EnteroPatho NPs lead to TJ disruption and paracellular protein delivery, giving rise to a general platform for oral delivery.

Indexed as

NanoparticlesTight JunctionsAnimalsCaco-2 CellsDrug CarriersDrug Delivery SystemsHumansIntestinal MucosaProteinsDrug CarriersProteinsdual releaseglycocalyxnanoparticleoral deliveryparacellular permeabilitytight junction

Identifiers

PMID39096293
PMCPMC12090900

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.